KRAS and acute lymphoblastic leukemia: A significant proportion of patients harbours mutations in FLT3 (~25%), NRAS/KRAS (~15%) or PTNP11 genes (~10%), which are also involved in other paediatric pro- and pre-B ALL [263–265].